PharmaCieloPCLOF +5.10% Debt-to-Equity is -1.21 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 809 Drug Manufacturers companies, PharmaCielo ranks worse than 123609.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PharmaCielo's Debt-to-Equity or its related term are showing as below:
PCLOF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -10.9 Med: 0.04 Max: 6.03
Current: -1.21
During the past 7 years, the highest Debt-to-Equity Ratio of PharmaCielo was 6.03. The lowest was -10.90. And the median was 0.04.
PCLOF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.27
vs PCLOF: -1.21
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PharmaCielo Debt-to-Equity Related Terms
PharmaCielo Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PharmaCielo's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PharmaCielo's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCielo (PCLOF) has a Debt-to-Equity of -1.21 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PharmaCielo and its competitors. According to the industry distribution chart, PharmaCielo ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is PharmaCielo's Debt-to-Equity too high?
PharmaCielo's current Debt-to-Equity is -1.21. Based on the distribution chart, PharmaCielo ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #999999 out of 809 companies for Debt-to-Equity. This places PharmaCielo in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current Debt-to-Equity is -1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.09, compared to a current price of $0.05 — trading 41.6% below its estimated fair value. The current Debt-to-Equity is -1.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Debt-to-Equity is -1.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 